Introduction
- CAR-T cell therapy stands for chimeric antigen receptor T-cell therapy. It is a type of cancer treatment in which a patient’s own T cells are collected and genetically changed in the laboratory so they can better recognize and kill cancer cells.
Basic meaning
- In this therapy, doctors remove T cells from the patient’s blood, add the gene for a special receptor called a CAR, multiply those modified cells, and then infuse them back into the patient. The engineered cells are then expected to find and attack cancer cells carrying the target antigen.
Why it is called “CAR-T”
- CAR means chimeric antigen receptor, which is the artificial receptor added to the T cells.
- T refers to T lymphocytes, the immune cells used in the treatment.
- So CAR-T therapy is essentially genetically engineered T-cell therapy.
Main objective
- The main aim of CAR-T therapy is to make the patient’s immune system attack cancer more effectively, especially when the disease has relapsed or not responded to standard treatments.
How it works
- Cancer cells can escape normal immune surveillance. CAR-T therapy bypasses part of that problem by giving T cells a receptor designed to bind a chosen target on cancer cells.
- Once these engineered T cells attach to the cancer cells, they can activate and kill them.
Step-by-step process
- The broad treatment process usually includes:
- collecting white blood cells, including T cells, from the patient through apheresis
- modifying the T cells in the lab to express the CAR
- growing large numbers of those cells
- giving the cells back to the patient by infusion
- This whole process is personalized for each patient.
Nature of the therapy
- CAR-T is a form of personalized or individualized treatment because the therapy is typically made from the patient’s own cells.
- NHS England describes it as a treatment specifically developed for each individual patient.
Which cancers it is used for
- CAR-T therapy is currently used mainly for certain blood cancers, especially some:
- leukemias
- lymphomas
- multiple myeloma
- It is not yet a routine standard treatment for most solid tumors, although research is ongoing.
Current approved products
- FDA’s current list of approved cellular and gene therapy products includes multiple CAR-T products. Examples include:
- Kymriah (tisagenlecleucel)
- Yescarta (axicabtagene ciloleucel)
- Tecartus (brexucabtagene autoleucel)
- Breyanzi (lisocabtagene maraleucel)
- Abecma (idecabtagene vicleucel)
- Carvykti (ciltacabtagene autoleucel)
Example of recent development
- A recent example of expanding use is the FDA approval in December 2025 of Breyanzi for adults with relapsed or refractory marginal zone lymphoma after at least two prior lines of systemic therapy.
Main targets used
- Many currently approved CAR-T therapies target CD19 or BCMA, depending on the blood cancer being treated.
- For example, Breyanzi is described by FDA as a CD19-directed genetically modified autologous T-cell immunotherapy.
Benefits
- CAR-T therapy can produce very strong responses in some patients whose cancer has come back or has not improved with other treatments.
- In some cases, it can lead to long remission.
Why it is important
- CAR-T therapy is important because it represents a major shift in cancer treatment: instead of only using drugs to attack cancer directly, it uses engineered immune cells as the treatment itself.
- It is one of the best-known examples of advanced cell therapy in oncology.
Major risks and side effects
- CAR-T therapy can cause serious side effects, and this is one reason it is delivered in specialized centers.
- The most important risks classically include:
- cytokine release syndrome (CRS)
- neurologic toxicity / immune effector cell-associated neurotoxicity syndrome (ICANS)
- infections
- prolonged low blood counts
- These toxicities can become severe and need close monitoring.
Need for specialist centres
- Because CAR-T therapy is complex and can be dangerous if complications are not managed quickly, it is usually provided through specialized hospitals or designated centres with trained staff and intensive monitoring systems.
Recent regulatory change
- In the U.S., the FDA announced in June 2025 that it was eliminating the REMS requirement for autologous CAR-T therapies, stating that the benefits of these products still outweighed the risks without that additional REMS system.
- This did not mean CAR-T became risk-free; it meant the regulatory oversight model changed.
India context
- CAR-T is also important in India because NexCAR19 became the first CAR-T therapy designed and approved in India in late 2023.
- NCI described it as a homegrown therapy aimed at making CAR-T more accessible in the Indian setting.
Limitations
- CAR-T therapy has important limitations:
- it is expensive and technically demanding
- it is usually not the first treatment used
- it is mostly established for selected hematologic cancers
- manufacturing takes time because the product is individualized
- Access and logistics remain major challenges globally.
Research direction
- Research is now focused on:
- making CAR-T safer
- improving durability of response
- expanding it to more cancers, especially solid tumors
- developing newer targets and better cell-engineering strategies
- NCI’s recent coverage of GD2 CAR-T in diffuse midline gliomas is one example of this ongoing expansion effort.
Key points to remember
- CAR-T = chimeric antigen receptor T-cell therapy.
- It uses a patient’s own T cells, which are genetically modified and reinfused.
- It is mainly used for certain blood cancers.
- It is highly personalized and usually delivered in specialist centres.
- Major toxicities include CRS and neurologic side effects.
Conclusion
- CAR-T cell therapy is an advanced form of cancer immunotherapy in which a patient’s own T cells are engineered to attack cancer.
- It has become one of the most important breakthroughs in modern treatment of some blood cancers, but it remains complex, expensive, and associated with serious risks that require specialist care.
